Kidney and Blood Pressure Research

Original Paper

Free Access

Estimation of Oxidative Stress Markers in Chronic Kidney Disease

Kuchta A.a · Pacanis A.a · Kortas-Stempak B.a · Çwiklińska A.a · Ziętkiewicz M.b · Renke M.c · Rutkowski B.c

Author affiliations

Departments of aClinical Chemistry, bInternal Diseases, Connective Tissue Diseases and Geriatrics, and cNephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland

Corresponding Author

Agnieszka Kuchta

Department of Clinical Chemistry

Medical University of Gdańsk

Dębinki 7, PL–80-220 Gdańsk (Poland)

Tel. +48 58 349 27 95, Fax +48 58 346 15 38, E-Mail agastencel@gumed.edu.pl

Keywords: Chronic kidney diseaseOxidized low-density lipoproteinParaoxonase-1

Related Articles for ""
Kidney Blood Press Res 2011;34:12–19
https://doi.org/10.1159/000321508

Abstract

Changes mediated by oxidative stress are thought to be involved with atherosclerosis in patients with chronic kidney disease (CKD). The purpose of this study was to analyze the markers of oxidative damage and the activity of antioxidative enzymes as well as the total antioxidant capability in patients with different stages of CKD, both conventionally treated and dialyzed. We evaluated the oxidative modification of lipids (by oxidized low-density lipoprotein and malonodialdehyde levels) and proteins (by advanced oxidation protein products level). We also assessed the activity of paraoxonase-1 and glutathione peroxidases and total antioxidant status. Compared with the control group, the uremic patients, both dialyzed and nondialyzed, had higher levels of all studied plasma oxidative stress markers and decreased activity of antioxidative enzymes. Our results lead us to conclude that oxidative stress seems to be related rather to the uremic state than to the dialysis treatment. We also showed that estimating total antioxidant status in a simple test is unreliable for assessing the antioxidant ability of patients with CKD.

© 2010 S. Karger AG, Basel



Related Articles:

References

  1. Tylicki L, Rutkowski B, Horl WH: Antioxidants: a possible role in kidney protection. Kidney Blood Press Res 2003;26:303–314.
    External Resources
  2. Araujo M, Welch WJ: Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 2006;15:72–77.
    External Resources
  3. Przekwas M, Malgorzewicz S, Zdrojewski Z, et al: Influence of predialysis oxidative stress on peroxidation processes after renal transplantation. Transplant Proc 2003;35:2170–2173.
    External Resources
  4. Vaziri ND: Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004;13:93–99.
    External Resources
  5. Rutkowski P, Malgorzewicz S, Slominska E, et al: Interrelationship between uremic toxicity and oxidative stress. J Ren Nutr 2006;16:190–193.
    External Resources
  6. Kitiyakara C, Gonin J, Massy Z, Wilcox CS: Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 2000;9:477–487.
    External Resources
  7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
    External Resources
  8. Oberg BP, McMenamin E, Lucas FL, et al: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009–1016.
    External Resources
  9. Himmelfarb J, Lazarus JM, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991;17:271–276.
    External Resources
  10. Ward RA, McLeish KR: Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003;27:230–236.
    External Resources
  11. Samouilidou EC, Grapsa EJ, Kakavas I, et al: Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol 2003;35:393–397.
    External Resources
  12. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21:845–853.
    External Resources
  13. Ozden M, Maral H, Akaydin D, et al: Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem 2002;35:269–273.
    External Resources
  14. Getz GS, Reardon CA: Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004;15:261–267.
    External Resources
  15. Wang Y, Fang X, Wang S, et al: Relation between plasma oxLDL antibodies and oxLDL in the circulation. Inflammation 2007;30:7–13.
    External Resources
  16. Kaneda H, Taguchi J, Ogasawara K, et al: Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002;162:221–225.
    External Resources
  17. Wilson DW, Metz HN, Graver LM, Rao PS: Direct method for quantification of free malondialdehyde with high-performance capillary electrophoresis in biological samples. Clin Chem 1997;43:1982–1984.
    External Resources
  18. Anderstam B, Ann-Christin BH, Valli A, et al: Modification of the oxidative stress biomarker AOPP assay: application in uremic samples. Clin Chim Acta 2008;393:114–118.
    External Resources
  19. MacKness B, Mackness MI, Durrington PN, et al: Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000;30:4–10.
    External Resources
  20. Zachara BA, Wlodarczyk Z, Andruszkiewicz J, et al: Glutathione and glutathione peroxidase activities in blood of patients in early stages following kidney transplantation. Ren Fail 2005;27:751–755.
    External Resources
  21. Zachara BA, Salak A, Koterska D, et al: Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure. J Trace Elem Med Biol 2004;17:291–299.
    External Resources
  22. Avissar N, Ornt DB, Yagil Y, et al: Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994;266:C367–C375.
    External Resources
  23. Zachara BA, Trafikowska U, Adamowicz A, et al: Selenium, glutathione peroxidases, and some other antioxidant parameters in blood of patients with chronic renal failure. J Trace Elem Med Biol 12001;5:161–166.
  24. Sutherland WH, de Jong SA, Walker RJ: Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 2004;19:75–82.
    External Resources
  25. Schiavon R, Battaglia P, De Fanti E, et al: HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002;324:39–44.
    External Resources
  26. Schiavon R, De Fanti E, Giavarina D, et al: Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71–80.
    External Resources
  27. Palleschi S, De Angelis S, Diana L, et al: Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clin Chem Lab Med 2007;45:1211–1218.
    External Resources
  28. Boaz M, Matas Z, Biro A, et al: Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999;56:1078–1083.
    External Resources
  29. Yoshimura S, Suemizu H, Nomoto Y, et al: Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996;73:207–211.
    External Resources
  30. Holvoet P, Harris TB, Tracy RP, et al: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol 2003;23:1444–1448.
    External Resources
  31. Takenaka T, Takahashi K, Kobayashi T, et al: Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol 2002;58:33–37.
    External Resources
  32. Diepeveen SH, Verhoeven GH, van der Palen J, et al: Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 2004;98:c3–c7.
    External Resources
  33. Liu SX, Hou FF, Guo ZJ, et al: Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006;26:1156–1162.
    External Resources
  34. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524–2532.
    External Resources
  35. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304–1313.
    External Resources
  36. Capeillere-Blandin C, Gausson V, Nguyen AT, et al: Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant 2006;21:1555–1563.
    External Resources
  37. Boulanger E, Moranne O, Wautier MP, et al: Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int 2006;26:207–212.
    External Resources
  38. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858–6862.
    External Resources
  39. Verdecchia P, Schillaci G, Reboldi G, et al: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072–1078.
    External Resources
  40. Capasso G, Jaeger P, Robertson WG, Unwin RJ: Uric acid and the kidney: urate transport, stone disease and progressive renal failure. Curr Pharm Des 2005;11:4153–4159.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 02, 2010
Accepted: September 24, 2010
Published online: November 11, 2010
Issue release date: January 2011

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2011, Vol.34, No. 1

January 2011

Article

Recommend This
Open Access Gateway
TOP